Actavis are pleased to announce the launch of Losartan Tablets in the UK on the first day of patent expiry, March 1st.

Actavis worked hard to launch at patent expiry, delivering stock direct to customers for day one in order to support them with the significant impact patent expiry launches have on the profitability of pharmacy and wholesalers.

Losartan 25mg, 50mg and 100mg Tablets, the generic equivalent of MSD’s Cozaar, have been introduced in Actavis livery as part of Actavis’ commitment to providing customers with a broad portfolio of products.

Michael Cann, Director Generics at Actavis says: “The addition of these products, including another day one patent expiry, is an excellent extension to our broad portfolio.”

For more information, please contact:
Donna Wright, Lexis PR
Tel: 020 7908 6496 / 07984 550 312, Email: dwright@lexispr.com